BSE filing, NSE: PPLPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Piramal Pharma Ltd: key numbers
- Share price
- ₹238.91
- Market cap
- ₹31,807 Cr
- Revenue (annual)
- ₹8,869 Cr
- Net profit (annual)
- ₹-325.9 Cr
- P/E (TTM)
- -152.3×Sector 45.9×
- Promoter holding
- 34.80%+0.00% QoQ
- FII holding
- 13.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Piramal Pharma Ltd
All →Piramal Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹2,617 Cr (+28% YoY), EBITDA margin 14.7% (+372 bps), PAT ₹5 Cr vs loss of ₹99 Cr. FY27 revenue growth outlook raised to 19-20%.
Piramal Pharma Results Update
Piramal Pharma released its Q2/H1 FY27 press release reporting revenue of Rs. 2,617 crore for Q2 and Rs. 4,887 crore for H1, with EBITDA up 72%. The filing also upgrades FY27 revenue growth guidance to 19–20%.
Piramal Pharma Q2 FY27 Results: Turns Profitable, Net Profit ₹5 Cr
Piramal Pharma Ltd reported revenue from operations of ₹2,617 Cr (+28.1% YoY) and net profit of ₹5 Cr for Q2 FY27.
- Key figure
- Net profit ₹5 Cr
Piramal Pharma Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026. The report details equity distribution among promoters and public shareholders.
Piramal Pharma Board Meeting Date
Piramal Pharma Limited has scheduled a board meeting on October 27, 2026. The board will consider and approve unaudited financial results for the quarter ended September 30, 2026.
Piramal Pharma Adverse Business Impact
Piramal Pharma announced that its sales and distribution arrangement with Bayer Pharmaceuticals will expire on December 31, 2026, and will not be renewed.
- From
- Bayer Pharmaceuticals Private Limited
Other capital structure change announcements
All →First Fintec Capital Structure Change
Vipin Vishvanath Agarwal acquired 8,32,220 First Fintec shares, about 8%, off-market. As a non-promoter, this SAST disclosure records a listed-equity stake change.
PC Jeweller Capital Structure Change
UNICO Global Opportunities Fund, a non-promoter, sold 13.86 crore PC Jeweller shares in market sales from July to October 2026. Its stake fell from 4.97% to 2.97%.
Rane Holdings Capital Structure Change
Rane Holdings took up 5,15,954 rights shares in its 49%-owned JV, ZF LIFETEC Rane Automotive. No consideration is disclosed, and its stake stays at 49%.
Automobile Corporation Of Goa Capital Structure Change
Automobile Corporation of Goa filed its buyback letter of offer for 1,44,639 shares at Rs 2,005 each. Up to Rs 29.00 Crore tender buyback opens November 3.
- Value
- ₹29.00 Cr
Advanced Enzyme Technologies Capital Structure Change
Advanced Enzyme closed its buyback after purchasing 2,410,906 shares for ₹69.70 Crore. Closure took effect October 30, 2026, ahead of the scheduled period.
- Value
- ₹69.70 Cr
- Execution
- August 14, 2026 to October 30, 2026
Medi Assist Healthcare Services Capital Structure Change
Medi Assist Healthcare's board approved a tender-offer buyback of up to 11,59,199 shares at Rs 425 each, capped at Rs 49.27 Crore. The record date is 20 November 2026, and promoters will not participate.
- Value
- ₹49.27 Cr